Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Income from Continuing Operations: 2009-2024

Historic Income from Continuing Operations for Corcept Therapeutics (CORT) over the last 12 years, with Dec 2024 value amounting to $141.2 million.

  • Corcept Therapeutics' Income from Continuing Operations fell 58.34% to $19.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $106.2 million, marking a year-over-year decrease of 25.15%. This contributed to the annual value of $141.2 million for FY2024, which is 33.04% up from last year.
  • Per Corcept Therapeutics' latest filing, its Income from Continuing Operations stood at $141.2 million for FY2024, which was up 33.04% from $106.1 million recorded in FY2023.
  • In the past 5 years, Corcept Therapeutics' Income from Continuing Operations registered a high of $141.2 million during FY2024, and its lowest value of $101.4 million during FY2022.
  • For the 3-year period, Corcept Therapeutics' Income from Continuing Operations averaged around $116.3 million, with its median value being $106.1 million (2023).
  • As far as peak fluctuations go, Corcept Therapeutics' Income from Continuing Operations fell by 9.86% in 2022, and later surged by 33.04% in 2024.
  • Over the past 5 years, Corcept Therapeutics' Income from Continuing Operations (Yearly) stood at $106.0 million in 2020, then rose by 6.13% to $112.5 million in 2021, then fell by 9.86% to $101.4 million in 2022, then rose by 4.66% to $106.1 million in 2023, then skyrocketed by 33.04% to $141.2 million in 2024.